Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2381786
Max Phase: Preclinical
Molecular Formula: C28H34N4O2
Molecular Weight: 458.61
Molecule Type: Small molecule
Associated Items:
ID: ALA2381786
Max Phase: Preclinical
Molecular Formula: C28H34N4O2
Molecular Weight: 458.61
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CCCCCn1cc(C(=O)NC23CC4CC(CC(C4)C2)C3)c(=O)n2nc(-c3ccccc3)cc12
Standard InChI: InChI=1S/C28H34N4O2/c1-2-3-7-10-31-18-23(26(33)29-28-15-19-11-20(16-28)13-21(12-19)17-28)27(34)32-25(31)14-24(30-32)22-8-5-4-6-9-22/h4-6,8-9,14,18-21H,2-3,7,10-13,15-17H2,1H3,(H,29,33)
Standard InChI Key: JEUUPPZWHDFNDP-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 458.61 | Molecular Weight (Monoisotopic): 458.2682 | AlogP: 5.05 | #Rotatable Bonds: 7 |
Polar Surface Area: 68.40 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 6 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: | CX LogP: 4.84 | CX LogD: 4.84 |
Aromatic Rings: 3 | Heavy Atoms: 34 | QED Weighted: 0.50 | Np Likeness Score: -1.08 |
1. Aghazadeh Tabrizi M, Baraldi PG, Saponaro G, Moorman AR, Romagnoli R, Preti D, Baraldi S, Ruggiero E, Tintori C, Tuccinardi T, Vincenzi F, Borea PA, Varani K.. (2013) Discovery of 7-oxopyrazolo[1,5-a]pyrimidine-6-carboxamides as potent and selective CB(2) cannabinoid receptor inverse agonists., 56 (11): [PMID:23697626] [10.1021/jm400182t] |
Source(1):